Kiromic Biopharma is a biotechnology business based in the US. Kiromic Biopharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.06 – a decrease of 5.38% over the previous week. Kiromic Biopharma employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.06 |
|---|---|
| 52-week range | $0.05 - $3.32 |
| 50-day moving average | $0.97 |
| 200-day moving average | $1.25 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.17 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0615 from 2025-05-02
| 1 week (2025-04-28) | 22.02% |
|---|---|
| 1 month (2025-04-04) | -48.75% |
| 3 months (2025-02-05) | -95.34% |
| 6 months (2024-11-05) | -94.51% |
| 1 year (2024-05-03) | -97.48% |
|---|---|
| 2 years (2023-05-04) | -98.80% |
| 3 years (2022-05-04) | 16.47 |
| 5 years (2020-05-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -143.47% |
| Return on equity TTM | -1129.81% |
| Profit margin | 0% |
| Book value | $-8.21 |
| Market Capitalization | $214,931 |
TTM: trailing 12 months
We're not expecting Kiromic Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Kiromic Biopharma's shares were split on a 1:30 basis on 12 March 2023 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kiromic Biopharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Kiromic Biopharma shares which in turn could have impacted Kiromic Biopharma's share price.
Over the last 12 months, Kiromic Biopharma's shares have ranged in value from as little as $0.0504 up to $3.315. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiromic Biopharma's is 1.659. This would suggest that Kiromic Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Kiromic Biopharma's beta into context you can compare it against those of similar companies.
Kiromic BioPharma, Inc. , a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.